-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EAHGQDaInRL9pLv+8gFigjyPesumEKqgz0D1yQjBz+r52NYLNEc2CH8tbjVviSZy
 S5rPMTGCtZjFwYJAJGeaCQ==

<SEC-DOCUMENT>0001075880-07-000043.txt : 20070813
<SEC-HEADER>0001075880-07-000043.hdr.sgml : 20070813
<ACCEPTANCE-DATETIME>20070813080603
ACCESSION NUMBER:		0001075880-07-000043
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070810
FILED AS OF DATE:		20070813
DATE AS OF CHANGE:		20070813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		071047162

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20070813.htm
<DESCRIPTION>FORM 6K 2007 08 13
<TEXT>
<html>

  <head>
    <title>form6k20070813.htm</title>
<!-- Licensed to: Novogen-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman;"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>______________________________________________</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Form
      6-K</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>REPORT
      OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
      THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">For
      the
      month of August</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Commission
      File Number <font style="DISPLAY: inline; FONT-FAMILY: Arial, sans-serif;">________________</font></font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;">140
      Wicks
      Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Address
      of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">___________________________________</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Form
      20-F
<font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font><strong>&#160;</strong>Form
      40-F <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(l):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
      6-K if submitted solely to provide an attached annual report to security
      holders.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule lO1(b)(7):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
      6-K
      if submitted to furnish a report or other document that the registrant foreign
      private issuer must furnish and make public under the laws of the jurisdiction
      in which the registrant is incorporated, domiciled or legally organized (the
      registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
      which the registrant&#8217;s securities are traded, as long as the report or other
      document is not a press release, is not required to be and has not been
      distributed to the registrant&#8217;s security holders, and, if discussing a material
      event, has already been the subject of a Form 6-K submission or other Commission
      filing on EDGAR.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font><strong>&#160;</strong>No
      <font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf </strong>by the undersigned,
      thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>/s/&#160;&#160;Ron
      Erratt</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Ronald
      Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Company
      Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>Date
      13 August, 2007</strong></font></div>
    <div><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><img src="novogen103.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>ASX
      &amp; MEDIA RELEASE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>13
      AUGUST, 2007</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>NEWLY
      PUBLISHED RESEARCH INDICATES THE POTENTIAL OF PHENOXODIOL TO PROTECT AGAINST
      NEUROPATHY</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Novogen
      Limited&#8217;s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has made the
      following announcement:</font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Sydney,
      Australia and New Canaan, Conn., August 13 , 2007 &#8211; Results of a study published
      in the current issue of <u>BMC Neuroscience</u> show that investigational drug
      phenoxodiol, currently being developed as a therapy for late-stage,
      chemo-resistant prostate, ovarian and cervical cancers, may also have the
      potential to be use used in conjunction with cisplatin chemotherapy to prevent
      induction of platinum-induced neuropathy.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">The
      new
      study examined whether phenoxodiol could protect against cisplatin-induced
      neurite inhibition in PC12 cells as an indication of the potential to protect
      against neuropathy.&#160;&#160;In the study, the effect of phenoxodiol on
      cisplatin induced neurite toxicity was assessed by measurement of neurite
      outgrowth. Study results show the addition of phenoxodiol showed no cytotoxicity
      at low doses and blocked the cisplatin induced neurite toxicity.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">The
      study
      concludes that successful prophylactic treatment of cisplatin induced neuropathy
      with phenoxodiol could allow more intensive and hence more effective cisplatin
      therapy.&#160;&#160;Overall, given the dose and treatment limiting neuropathic
      side effects of cisplatin, one of the most widely used chemotherapeutic drugs,
      and the lack of any currently available prophylactic treatment or cure, the
      study also concludes that phenoxodiol is a promising candidate that warrants
      further testing.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">"Historical
      data demonstrates that phenoxodiol has the ability to overcome drug resistance
      in cancer cells,&#8221; said Dr. Ann Turnley, Associate Director, Centre for
      Neuroscience, University of Melbourne.&#160;&#160;&#8220;This study&#160;indicates
      that phenoxodiol has the potential to protect normal cells from the toxic
      effects of chemotherapy and may help in reducing some of the side
      effects."</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">The
      title
      of the new research article is <em>Phenoxodiol protects against Cisplatin
      induced neurite toxicity in a PC-12 cell model</em>&#8211; and may be downloaded at
<u>http://www.biomedcentral.com/1471-2202/8/61</u>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Oral
      phenoxodiol in combination with weekly carboplatin is currently being studied
      in
      a multi-national Phase III clinical trial called OVATURE. The OVATURE trial
      is
      taking place in the United States, Europe, and Australia and is designed to
      demonstrate the safety and effectiveness of phenoxodiol in combination with
      weekly carboplatin compared to weekly carboplatin alone for the treatment of
      ovarian cancer that has become resistant or refractory to platinum therapy.
      More
      information about the OVATURE trial is available at
<u>http://clinicaltrials.gov/</u> and type in &#8220;OVATURE&#8221; in the search
      option.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>About
      phenoxodiol:</strong> Phenoxodiol is being developed as a therapy for
      late-stage, chemo-resistant prostate, ovarian and cervical cancers. Phenoxodiol
      is an investigational drug and, as such, is not commercially available. It
      is a
      novel-acting drug that inhibits key pro-survival signaling pathways operating
      via sphingosine-1-phosphate and Akt. Inhibition of these pathways leads to
      prevention of phosphorylation of key anti-apoptotic proteins such as XIAP.
      Loss
      of activity of these proteins restores the ability of chemoresistant tumor
      cells
      to undergo apoptosis in response to chemotherapy. The putative molecular target
      for phenoxodiol is a tumor-specific protein, accounting for the highly selective
      nature of the drug.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>A</strong><strong>bout
      Marshall Edwards Inc:</strong> Marshall Edwards, Inc. (Nasdaq: MSHL) is a
      specialist oncology company focused on the clinical development of novel
      anti-cancer therapeutics. These derive from a flavonoid technology platform
      which has generated a number of novel compounds characterized by broad ranging
      efficacy against a range of cancer targets with few side effects. The unique
      combination of efficacy and safety has been explained by their ability to target
      an enzyme present on the surface of cancer cells, thereby inhibiting the
      production of pro-survival proteins within the cell. Marshall Edwards, Inc.
      has
      licensed rights from Novogen Limited (Nasdaq: NVGN) to bring three oncology
      drugs - phenoxodiol, NV-196 and NV-143 - to market globally. Marshall Edwards,
      Inc. is majority owned by Novogen, an Australian biotechnology company that
      is
      specializing in the development of therapeutics based on a flavonoid technology
      platform. Novogen, based in Sydney, Australia, is developing a range of
      therapeutics across the fields of oncology, cardiovascular disease and
      inflammatory diseases. More information on phenoxodiol and on the Novogen group
      of companies can be found at <u>www.marshalledwardsinc.com</u> and
<u>www.novogen.com</u>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><em>Under
      U.S. law, a new drug cannot be marketed until it has been investigated in
      clinical trials and approved by the FDA as being safe and effective for the
      intended use. Statements included in this press release that are not historical
      in nature are "forward-looking statements" within the meaning of the "safe
      harbor" provisions of the Private Securities Litigation Reform Act of 1995.
      You
      should be aware that our actual results could differ materially from those
      contained in the forward-looking statements, which are based on management's
      current expectations and are subject to a number of risks and uncertainties,
      including, but not limited to, our failure to successfully commercialize our
      product candidates; costs and delays in the development and/or FDA approval,
      or
      the failure to obtain such approval, of our product candidates; uncertainties
      in
      clinical trial results; our inability to maintain or enter into, and the risks
      resulting from our dependence upon, collaboration or contractual arrangements
      necessary for the development, manufacture, commercialization, marketing, sales
      and distribution of any products; competitive factors; our inability to protect
      our patents or proprietary rights and obtain necessary rights to third arty
      patents and intellectual property to operate our business; our inability to
      operate our business without infringing the patents and proprietary rights
      of
      others; general economic conditions; the failure of any products to gain market
      acceptance; our inability to obtain any additional required financing;
      technological changes; government regulation; changes in industry practice;
      and
      one-time events. We do not intend to update any of these factors or to publicly
      announce the results of any revisions to these forward-looking
      statements.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br></body>
</html>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogen103.jpg
<TEXT>
begin 644 novogen103.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!P17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@#`P#$!`@`9````3@``````
M``!@`````0```&`````!````141'05)I>F5R(%-O9G1W87)E(%-U:71E`(#_
MVP!#``(!`0$!`0(!`0$"`@("`@0#`@("`@4$!`,$!@4&!@8%!@8&!PD(!@<)
M!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_VP!#`0("`@("`@4#`P4*!P8'"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@K_P``1"`"G`<(#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#]_****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"N)TG7(#\<-=\*JP5H?"VEW*1XYP]SJ2D_^0Q7;5\K^(OC3;^!?^"L>A_"
M_5+E$C\<_!QTTR)I<;[NQO[B9E''S,8I9&`XP(R><\7%-[')BJT*+@Y/=I'U
M);'Y-O<`9J2JUA,T^Y]@"E5VD-G/7^F/SJS4O<Z[W"BBBD`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!7X]_\`!?\`^*7BK]FW]NCX#?M&>"9BM]X?TVZGC/.V18KF,R1G'9D=
MD)Z[6/K7["=:_';_`(.DO#@C/PB\8",X@.J6*MV^80N!_P"0Z[\M498M1:NF
M?+<82E2R:56'Q1::/U'_`&7?CGX)_:2^"/A_XV_#W4%N-*\0:7!=0@'YH6*#
M=$X[.C94CU!KT+(/0U_/E_P12_X*C2_L8_$5_@K\6=5_XMWXIOX\74B?\@6\
M9BHF&#S&V[Y^"?D4]`:_?7P_KNEZ_I$6M:)?Q75K<PK);7$+;DE1AD,I'!!'
M(]0:C'86>&JOL;\.9[A\YP*DI>_%*Z-BBCI17&?1!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`449'K10`4444`%%%%`!1110`4444`%%&0>AHH`
M***,@]#0`5^87_!SIX*DU?\`9,\&^-4CR-'\;+"YV<J)[>4`Y],Q'\Q7Z>U\
M9?\`!<_X5M\0O^"9?Q"2RM3+<Z$+#6+968D@07D+3'/M#YWYUTX.3AB8R1XG
M$5%XC):\%ORM_<?SGF3R6,!7((PQSU!SD?C7Z8?\$8?^"QU_\#-7L?V6OVH/
M$C/X-N1Y/A?Q%?SD_P!CS,V5MI6.3Y#$L`3]S`'0"OS,G1@0Q;)R<^XZ`_F#
M3S=)*@5U'`(!QR*^NQ%&&)ARR/P'*<VQ.2XR-:CTW1_7AIFNV6K6D=[8S1RQ
M2*"DB2`JP(R"#T(]".#5Q6W?_KK\5?\`@B)_P5VO/`VN:9^QY^T[XHEET6[G
M\CP7XEOI<_8VV#9:2N?^69;Y4)R59U0GFOVCL)4E3S$;(95*\Y&.>]?(XO#3
MPM7E9_0&29SA\YP:K4WKU78L4445S'LA1110`4449%`!111D>M`!1110`449
M'3-%`!1110`4444`%%&1ZT4`%%&1ZT4`%%!('4T4`%%%%`!11D>M&1ZB@`HH
MR#T-%`!1110`449`ZFC(]:`"BBB@`HHR!U-%`!1110!CCQ;X:;Y5UVR)/11,
M.:N:;JFFZ@C/97<4R@`DPG<._I]#7\L3Z[J[J4;5;O!ZXN#7Z`_\$-/V_KOX
M3_$^3]F+XG:T&T3Q=>)_PCEU=S$+9:FQ*K""<X28E5`SPX`&=_'@8?/J5>NJ
M;5KGZGGWA;CLEP,\13J^TY5>R70_:=65E#J>#TI:J6U])+"K_9^&4L.<=^E6
MQTKWS\KOJ(V`<FLW5_$FB:4WDZEJD,#XR$=\''KBK\_0#-?C7_P<<ZAJ%C^T
M=X)6QNWB\WPPY8HQ'/G,,\$9/3KGI7+C,3]4H>T/>X:R&?$F<1P*ER\UW?TW
M/V#TG7M(UR#S])U&*YB5RK/"^X*<9P<=#R./>M.,`$L.X%?G1_P;C7&H7W[+
M?C*>_P!1FGQ\0IE3SY2Y5?L%EP"Q)QG<?^!5^BJ-MXQTHPM=8BBJO<Y,ZRQY
M+FM3!.7-R.UR2H97$:;V'%.,[`X*C\Z^>?VYO^"BWP6_8B^'O_"0^-;A;_7+
MQ&_L7PW:W2"XO&4X8Y_Y9HI/+GC/`R2`=ZE2%&'/-V1R87"8G'5XT</'FD]%
M8^@%O;91F255STR<9KA_'/[3W[/GP[NFL?&WQF\-:7,K;6AO=7AC=3Z$,V17
MX2?M3?\`!5W]K?\`:GU>YAN/']YX7\.3RNB:%X;O)+>,Q$`[99E(>7`X.Y@A
MSRO-<7\(OV#?VS_VA[=?$7P\^!GB?5+2?YEU6_A,$++TW1RW!C60<8RA8<<5
MXTLZC4J.%"#D?J.'\+7A*,:V;8J-)-7M=7/WPT+]NO\`9!\42+;Z'^T?X0F=
MVP@.N0J"?Q:O1]!\5^'O$%H-0T;7;.]MY,>5/9SB1'^A4D&OY\_%7_!)3_@H
M9X/TXZWJO[-VJW"1+ND_LV^M[F1![)'(9&^B@FO./AW\;/VGOV3/&[GP1XS\
M3>$-7MI@MUITC2P[BI.%FMY!AP/FX8'&3TS6+SNO3E:K2:1HO#++,?%O+\PC
M*72+:U/Z8O.\S)@8>N&%<E^T1\-;+XQ_`;Q=\+;JW2:/Q!X=O+`Q2?=8RPL@
MS^)%?!/_``3O_P""Z6@?%W5-/^$/[4MI9:#KEQB&R\3POLLKURV%1P?]0Y&,
M98@D'[N=H_1O[:MQ8F6T*RJ0<$-U!Z&O:PF,I5Z<:E+8_,L^X?S+**D\)C86
M=FK]'\S^1SQ#HE[X:U2X\-ZG$\=UI]P]M=1.FTI(F%88/3IT[<BJ-?4W_!9;
M]G^X_9]_X*"^/-,$&RR\2ZE)XBT\K'A2EY(TCJ.V%E\Q?H!TSBOEN-%<X9\?
MA7Z)AJT:E&+1_)V94)8;'U*;5K-DUHS9WB0JP!VL.H/]?ZU^X?\`P06_X*A7
M/Q^\$_\`#)OQU\1^=XP\,V"?\(WJ=VY:76+!`5VNQ^]/$`N3U=6#=0^/PV9R
M3QQ72_!SXL^.O@?\4=!^+7PVU>2PUS0-3BN["YC;'S*P)1A_$KKE&7H58@\&
MN?'8*.*@V]SU.&\\KY+CE):P>Z/ZU;<QM$/+'&.YJQTKQ#]@W]K'PO\`MA_L
MR^&?CGX7DA"ZI:E=2MUE):TNT++-$01G(<9&>JD&O;Z^-J1=.HX/H?T1AJ]/
M$X>-6GM)7#I4<L\,0WN3QZ*33I&((`&<@]Z\+_X*%?M'/^RU^RIXO^+<-TD-
MY;Z>;?1RSX)NY@8HL<'.'=6_X":RJ35.#D]D=>&H5,5B84::O*3LCUV?QOX3
MMLF?7[50OWBTX`'XUJ6TL<R^;$<AE!!QU!K^;S]@#X.>*?VG_P!L#P;\*QJ5
M^UE/J:W>LM'=,/*LX5\V0DCH#M,?^\P'>OZ-O#\)L-/AM$B(184"!CS]T<5Q
MX+&1QD.91L?2\5\-QX9Q,*'M>>4DI/R3-(G`ZU3:YLE(,THR>AP:\,_;C_X*
M&?!?]ACP0GB+XAW`OM6O&*:-X<L9P;J]8#J!_`@/!<\9(')(!_&C]K'_`(*X
M_M>_M0W]S;R>.[GPAX>D^6+0O#-]);@(3SYLX99)3Z\JI'&RHQF98?"RY'K+
ML5P_P9FW$252FE"EUE+8_=CQW^TK\`OAI<M9>//C%X<TJ>,9>WO-7A21!_M*
M6R/RKG-!_;N_8\\3W/V30OVC_"-Q(&P476H0<_BPK\"_A/\`L,_MC?M'6R:S
M\-_@1XAUBT?F/5I[<002AN=R23LBOTY*Y[9/2NM\3_\`!)'_`(*">'].:[N_
MV<;^^B@^\FG75K=2(3SS&DA)_`5P+.,8UI1=C["7AYD%"?LZV90Y_)Z']">D
M>*?#'B.QAU/1==L[RVN!F"XM;A7CD&,Y5E.#P.U7[9PY8AP1Q@"OYF/!'QF_
M:?\`V0OB`1X5\9^*O!NMVI'VO3[F66`L.0!-;O\`+(/<@CWS7Z<?\$Y_^"[6
MB_$K5+3X0?M96EEHFM7+Q0Z?XGB<QVEW(3M`F5LB%B=H#`["6QA>,].%SBA7
MER5%RR\SR,]\-\TRG#_6<+.->EU<=S]-:*K6.I1W\"W,&UT<91D?(;Z&K->P
M?G*=PH/2FRR&-=P7/':O(_VK?VT_@M^QU\/I_'WQDUU+1`=MC81.&N+V0CA(
MDZL>Y/11R3BIG.-.#G)V2-L/1K8JNJ-&+E)[)'J)O[2*,RRW2A=P'([GM7/>
M,_C5\)/A^BOXZ^)&B:0-F\#4M1CA.WUPY%?B)^UI_P`%LOVJ_P!H?49M$^%N
MMMX!\/898;?1ILWLBJ?O2W"\J2.=J;0,9SC->">"/V:_VO?VEKEM7\&?##QS
MXQ:X</)JK6MS<PR,Q)W//)\N3@\E@#CJ<5X<\ZO*V'AS(_3<O\,JSP_M<UQ4
M*'EU/Z"!^V_^R(SB)?VCO!Q+=`-<@Y_\>KJ_#?QX^"OC"X2S\*_%3PYJ4TA(
M2*QU>&5C@9/"L3T!K\"5_P""2G_!1<+]I'[+NJ$@<$ZGIY8?@9\UQ'C;]D']
MLCX+1MJ'C/X&^-M$MHL-)?V^DW7D]0`3+""@YP`<]3VZTEG&)7QTF=R\-\AK
MZ8?,X.79L_I174+25]B,C8&>/>K","N0N`.U?@+_`,$__P!O[]N?P3\;O"WP
MB^'_`(\OO$]KK>MV^F_\(]XDGENHXU:55;:[,9(BBLS,0Q`"\C@5^^6DO<2:
M7"]V`)3'^\"]-W?&:]3"8N&*H\]K-;GP/$W#&)X:Q4:56HIJ6JL^A:+*$!)^
ME9USXBT"TN7MKO5[:.0`$QRR@'!Z'!_G5R0%T4`]".W7FOQ)_P"#@/5=4L?V
MS-,M(-1G6-?"%NP6.8J-WFR@G'3)P/RIXO%+"4'5>I'#&0?ZQYI'!<_)=7N?
MM./%?AGOKEE_W_6D_P"$K\,_]!NR_P"_ZU_-G\+/V:?VL_C=X=;QA\(O@]XQ
M\1:5'</`^H:5932Q>:H4L@9006&\<5T__#`?_!0+_HV?XA?^"BX_^)KRXYS5
MDM*3/NZOAIE="JZ<\S@FM&K_`/!/Z)O^$J\-$9_MNRP.O[]:=!XK\.7;^3!K
M$#L.BI(">W8?6OYUF_8#_P""@GWA^S-\1"!UQI%QC_T&O>O^"97['G[9/P\_
M;6\&^-/B-\"/&.EZ'933&^U#5M)F6"%3#(`&8C'WMO7-:4<TQ%2I:5)I'FYE
MP+EF7X">(IYA";CT35_S/W$R#5>_U*PTU!-?7*1+@D,YP..M3K]T9]*^0/\`
M@N4UU!_P3Y\4WMI)L>*YL_G`Y`-Q&"`1R,C(KUJLU3I.?8^"P&$>.QE/#IV<
MFE]Y]4?\)AX8G?9'KEH2#C!F`_K5U+N$LH2,$,,A@*_EB_M[65/_`"&+PD<9
M%R1_*OVH_P""(W[?,O[1?PE'P2^)&L+/XO\`"=N%6:>8M)?V(&V.;)Y9@0RM
MUZHW\6!Y66YQ3QU5P:MV\S[SBOPWQ_#F7K%PJ\ZZKL??T9&XCOBG5#;.9)'.
MWY>-K`]:FKV3\XM8K7#0Q@%SP.Y%9C>-?"B7<EJWB"V$L;E)(_,&4(SD$=NA
M_*M&]ADE@<1S;&*D*VW.#ZU_-[_P4`US6X?VV/BO!)K5Z\<?CS50(S>.$"":
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MF+]L;]GR'3/%.LC_`(37PK$EGXAB9UW7*\B*[7CE77&>.'1ATKZ]R!P37\U/
M[&'[4?CW]AS]I&P^*.GVER#9SO9>)]%W8-Q;9(FB*G!5E*@C/0Q\]17]%_PQ
M^)W@OXO^!M*^(G@+5XK_`$K5K1+BSN8B</&PR#SR/0@\@@@\BOHLGQGMZ/LJ
MC]];GXGQ[PS#(LS=?#?[O5O*#[=U^)TD^"`:_&;_`(.0`#^TCX&SV\*N?_([
M5^RSLI..^17XT_\`!R!_R<EX'_[%1O\`TH:GG;_X3I'1X6K_`(S*C_AE^1]!
M_P#!M[Q^RGXR/_519O\`T@LZ_10D;]N>HK\Z?^#;X_\`&*WC+_LH<W_I#9U^
MBY568ENP%:91_N<3Q..K?ZUXJ_\`,_R/,OVJ?VC?"?[*/P5USXT^-ILVFDVQ
M:*V#A6N9CQ'"F?XG;`%?SK?'[XY_$K]JKXM:A\6/B+>2ZAK.K7(BM+=%+_9T
MW8CMXE/.Q"<`#DD^M?HC_P`''GQ[N+K7?!7[-NE7[+;P!M:U:->DCMNA@!^G
M[T_C7A__``0V_95L_P!H']J0?$;Q3IHNM#\!P+>2PS1Y6:^<LL(;_=(:;']\
M`]J\;-:\L=C5A(GZ3P'@L#PUPM5SW$1_>-/EOWZ?>?5__!+C_@C3X+\`>%M-
M^/'[4OABVU;Q1>QQW6E>'KZ/?;Z4A&Y#*A!$LX!SD\+G`&<U^C5AHNEZ3IZ6
M.G6,<$,8Q'%$H"J.P`'0"K5G%Y>?H/ZU/7TF&PU/"TE"*V/R'-\YS#/,7*OB
MJC=^E]$5?L=M(C12*'5AAE89!KP[]M']@;]G_P#;)\"OX?\`B+X+M4U6&-O[
M'\0V<"I>6,N`%9)!@D#C*'*D#ITKWNHKDD8(]#6E2C2K0<9JZ9P83$5\!5C4
MH2LT[H_FD_:Z_93^(G['OQGU'X4?$"RWO$OF:5J,$96+4;7(VS*3W7."ISM8
M$=1FOT\_X(8_\%"M4^-OA"?]F'XOZY)>>(_#UK]HT/4+B7,E_8C"&-L\M)&<
M$GNLBYY!SZ-_P6\_90L?V@/V4;[Q[I&CH_B'P0&U*QN`GS/;`#SX21R5*@-]
M8Q7X[_L=?'#4?V=OVF_!?QAT^[=/[(UJ$705MHEM7)BEC8#@YC=QGWKY50>4
M9@HI^Y(_?/;4?$#@R<JZ3Q%'JM]%I]Y^C/\`P<N_LIMXZ^"GA?\`:=\*Z-YN
MH>#;J33];:,'+V-R4\MFYY,<JA5]YSGH*_$ZXMM@RIQ[BOZO?B?\/_!O[1/P
M>U;X;^*[-;S1?%.C2VMW$QX:*6,C<O<,-P*GL0I[5_,1^UG^S;XT_9+_`&@_
M$O[/OCM#]JT"^*V]TR[5O+9@'AG7/9XV4^QW`X*D#]1RG$J4?9G\.>(635<-
MC5C8K=^]IM;3]#S.GQJQ0NAP58$$=B#D?RIE/B(`;-?0-I:GYC=K8_2O_@W)
M_;%G^$_QVU#]E?QEJ[#1?',+7.A!Y.+?4X@H*Y;H)8L@8_B11C+5^ZV1ZBOY
M'_A/\2?$7P;^)>@_%7PG<B'5/#NJ6]]9,6/^LBE$@''\)`9&'<-7]5'P1^)>
MA_&KX6^'?BSX78-IWB+1X-0L3NY\N6)9`#[@LP_"OE<WH*-7VBZG[7P!FCKX
M&6'F[RCJO\CLYY-K`>H.*_)7_@XT_:,GO-<\*?LPZ/J),,.-;UBWC8?,Q62.
M%6[\`R-CU(/4`C]6?$6HV6BZ0^JZF^R&VB>220C[@522WM@`U_-_^V/\8M7_
M`&N/VO?%?Q%TN.:ZEUSQ"+31+>-<EK='6"VC0>K(J'\SV-?%9[B)0PGLX;R/
MZ-\+\I6/SUXNJOW=&/,[[7/T`_X-SOV:([;P[XJ_:GUK3MHN[HZ)X?:099HD
MVR7#@^F]E3ZQFOT*_:C^/_@W]F'X'^(?C9XWO#%9:)I\DZQJ?GGDP=D2`]79
ML*!ZD5E?L<_`2V_9B_9T\*?!BQ@7&DZ:D=[)&`!+<L`TLGXN6-?G[_P<<_M`
MWT$/@?\`9KT*Y:..83ZUK<8;J1B.U!_V0WG,1URJUHY/+,J4E\21P\D^->.)
M4U\,I_=%:_H?G9^TM^T/\1_VJ/B_JOQ:^)NIF[O=2FVP6@;=#:0#`2"-<8"J
M!CIR2Q.2Q)_3O_@EK_P1I\)>!]+T[XZ_M8^%8=4\0W'[_2O#%ZI>WTU"ORM-
M&1B2;D\-E4(!QN'R_*?_``1"_92TW]H7]K3_`(3;Q1IJ3:#X%MUU*9)4W":]
M:0"V7GC@JSG'=/<5^\R(%4+C@5PY1@8XC_:JVLGL?9^)'$U3+9+(\LER4XI<
MS6FI0T[1=)TFT2RT_3X;:%%`CAAC"JH`P``.@]JG^S6I<.5!(Z$CI5FBOI.5
M7/Q'WGJW=G@W[8G["G[/?[87@.X\.?$WP5`=0\EAI>OVZ[;NS<\@H_IVVG*X
M)XK\&OVQ?V1_B-^QK\8KKX6^/87DA7<^AZLL;)'J%J#A9ESRK<_,O5#QG(S7
M]+K`E?EZ]J^-/^"V/[)%E^T?^R5J/C#3],637?`5M<ZSIT@`WO"J`W,0]=T2
M%@.[Q)UQ7E9IE]'$4_:)6DNQ^@\"<7X[(\>L-4GS4*CLT];7/'?^"%7_``4*
MUSXN^')OV4OBSX@:ZUOP[8^=X;O+E_WEY8J?FBSU=XLK[[&7.2*_2ZOYBOV5
MOC;J?[.?[0/A7XT:5=R1_P!C:Q#<7JQC)D@9]L\8_P!Z-B![*1W%?TS:=JUK
MJ=C#>VTRR+/$'C93D,",Y%3D^,GB*3IR=W$OQ(R&EDV;^VH1M2JJZ]>OYG*?
MM%?&7PQ^S_\`"C6/B]XTU-;72]"T^6ZNF+`%]@R$7/5F.%`[E@*_G9_:_P#V
ML_B9^V=\9[WXL?$"_F,<K^5HFEJ2(K*U!'EHBCN>&+'))8\XK]$_^#C?]HRZ
MTWPGX+_9OT"[=1J\\VK:['&Y4F&(I'`GIAI&E8CK^Y'J,_-/_!#+]DBS_:%_
M:G_X6%XLTM)=#\`01Z@T<JEQ/J#2+Y"\\;5VM(>^8X_>N',\15Q6+6%CMU/K
M.",!A.'.&ZG$.)2<]>2_X?>SZC_X)??\$8/!_A71M-^-O[7OA*'5M=N5$^F>
M%-07?!IH*Y5ID/#S<G@_*N!P6!V_I9HOAK0?#UBFF:'I,%G;QJ!'!;1A%08Z
M`#@#V%:84*,`=*6O>PV$HX6GRTT?DV<YWF6>XR6(Q<VV^G1%86D(X$>WUP<5
M#<Z+I=]9FUO+*.2,C:5<=JOT5NDK:GDJ\97B[,\BM?V+/V8=-^-MC^T+I/P?
MTFR\7V$$T,&KV<9B=Q(NTEU0A78#(#,"1N;!&37J<6(8C'M(VKG![5:P/2BB
M,(QO9;FE>M6Q$E*I)MI65W<KD_)GW7^8K\0?^#@\Y_;4TW_L3[;_`-&RU^WK
M_P"L;ZK_`#K\0?\`@X.Y_;4TT?\`4G6W_HV:O(SM7P27H?H7A9*,.+8.7\K/
ML;_@WE@CD_8?U$L@&/'M\=WOY%M_@*^^?*@_NC\J^!_^#>9T3]AK427`_P"*
M]OB1G_IWMZ^^MT`&1M_*N_`7EA(W['RO%C3XFQ7+I[[_`#&BWB8@@X`ZC'6F
M-:V[,=L*G=][MG_.*E6XB0X+*`>].9]V'09!Z&NKJ?/KW%?N2#I7R%_P7+D"
M_P#!.KQA'GEKBR_]*8Z^O:^/_P#@N?\`\H[/%W_7Q9?^E,=<^+_W:?H>]PY%
M3S[#1?\`/'\S\:OV&_V=+?\`:H_:#@^!]Q-Y<NL:+JAL9W)"PW,5C-+"_P`I
M!.)%3(.1ANE9_P`&OBC\7/V)OVD[3QCIMI/I/B#PIJK0:GI]PV`Z_=FMI`.-
MK(2.F1P1@@$>T_\`!#[!_P""DG@T#_GQU/\`](I:^E?^"]G[!,TT0_;-^'NB
M;!"D5MXTM[8`;UW;(KX@=QOV.?[NTX`0FOD<-AJE3`QK4='%L_H',\_I4>+9
MY1CG>A6BK7Z/5'Z1?LN_'_P9^TQ\'='^,?@6_$NGZQ813+&S#S+=R/GAD'\+
MHV58=B*]%!!&0:_#;_@B-^WJ/V>_B_\`\,\^/]4">$O&MU''8FY;"Z?J!)"@
M?W5DW%6ST(7.,&OVZL9;<VH:$;E;)#8ZGO7U.`Q4<70YENC\)XLR&IP[FLJ#
M^!N\7W3+$_$1^AK^:_\`X*$\?MO_`!='_4^:O_Z.>OZ4)_\`4GZ5_-A_P4)_
MY/@^+G_8^ZO_`.CGKS,^_AP]5^9]MX0ZYMB%_P!.S]-OV9/^3;?A[_V(^D_^
MD<5%2?LQ?\FU_#S_`+$;2?\`TCBHKK6QY567[V7JS\>O!0_XK/2!_P!12W_]
M&+7]07A>W^T^#;!&;@V,088Z@H,C\J_E^\#_`/(ZZ/\`]A6W_P#1JU_4+X*.
M?"M@A_Y\XL?]\"O.X<;E2FV?2^,S_?X677E9^.__``7:_8*7X1_$`?M5?#C3
M2-"\2W*KXF@MHPJ65^1M\\@=$E4-N_V\G^+C6_X(/_\`!0!_`WB\?L@?$[55
M_L[5YWG\)W%U/_J+DJ2]JA(QL;864<89B.=W'ZJ_&WX*>`OCU\.]6^%GQ&TI
M;W3=7LGMKB%C_"V""/<$`@]OQ-?SM?M2?L\_$O\`8<_:1U#X<ZS<7$&H:#?)
M>:'K$49C%S#NW074?<#Y<''\:N.F*>84IY=CEBX+W>I'">-P_&/#TLBQ;_?1
M5X-]?^&T/Z4+>=;D>8%&.""#U'-?C?\`\'('_)R7@8YZ^%'_`/2AJ^^?^"6/
M[;6G?MH?L\P:WJM_"/%.@+%8^*;-6`9)PI"2[>H215WCW+>E?`O_``<A'/[2
M'@7:?^97;_T>U=>;5*=?*G.&J9XWAU@L3EW'D<-65I04T_N/H/\`X-OE_P",
M5?&9_P"JB3#_`,D;.OT5D&3G/45^=?\`P;?_`/)JOC/_`+*+-_Z06=?HJW/Z
M?SK;*E_L,3YGCG7BG%_XOT/P/_X+J>)+K6_^"BOBO3)KG>NDZ;I5G&@;.P&R
M6<`^G,\A_$5]M_\`!N5X,M-._9/\4^+XPBW6J>/+B">0)R\,-K;&,$YZ@RR'
M_@5?%_\`P7C\*W/A_P#X*&ZWK.`!K>A:==H0@Y"VYMN?7F(5]@?\&W/Q#L]5
M_9\\:_#1[M/M6D>,#?>6#UAN;:)5/YP/^=>5A(0_MR4GN?I/$,:L_"O#>S>B
M<;GZ2VRE4&6[8Z5+3(?Z"GU]2?AK=V%,FC\SOC@T^HYG*E0.]%KBD[*YC^,?
M"FF>*_#&H^'=802VE]8RV]S$PR'C=&1@?JK$?C7\N.JZ<NF:K/IK2^8L%R\3
M-C&X*Y4GVX%?U"?$_P`;:9\//`>M^-M;G"6>D:9/>7+9'"11%R/TK^7>ZFN]
M7U9[J67#W,I;9@<LS$G]2:^8XE2_=/JG_D?MG@^I^SQDG\-E]_O']*_[%>MW
M?C']DKX;>+=3E$EQJO@'2+J=RO)D>RB=B?7):ODC_@NO_P`$UY_VL?A3%\=?
MA+HAN/'WA"V;%K;Q_/JMB`6>`=S(IPR=>K#C.:^QOV2_"DO@7]FCP!X)G4*V
MC^#-,LBH[>5:QQ_^RUW\EK#.I2;O^E?586K.DHS3ULC\-XAP%#-'B*$]G)_F
M?R%FQDC9XIB5DC8K)&1RC`X(/I4()0D$5^KO_!;G_@C[=^&+_4/VROV8?#$S
M:9(GF>-O#.GP;FM\')O85'.W!'F)CY=I88`(K\IK@JP5U7&[)QR>.,<D?_JK
M[3"XE8J-T?S=G.38K)L6Z51:=!/.!P#&/SK^@?\`X-WOC?+\5?\`@GS8^$[^
M^\^_\#>([S1959OF6#"7$!QV&R?8/^N9^@_GT'45^K/_``;`_%N;2OBI\3O@
MQ/>A%U32+35;:`GEG@D>-L#UVS+D]^/05R9O24L-=;H]W@+%?5<\2Z23/OG_
M`(+*_M%K^S[^Q)XC73K_`,C5_%D1T#2V1L.IN5*2LN.XBWX/8D5^7/\`P1,_
M9X'QS_;4TC6-8T83:+X&M3K=Y(02AF4K';H?]K>V[_=1J])_X."_VBY?B%^T
M7HGP)TS5!)9>"[*2:]1)1M-Y<E2RMC^Y"JX/4;LC!YKZU_X(*?LZ?\*G_9*_
MX6QK>G^3JGCR[-T"W#)9PLT4(/\`OX>0?[+BOS*<5CLTBEM`_M^A_P`8KX<R
MJ;5<4[>?+V^X^\)8R5(#``K\HQT-?@W_`,%U==N=8_;_`-7MKB=F%CH5C!&A
M/"C:S\?BQK]YI&`5]WW0.N.E?A/_`,%Z_"]WH?[>=WK,BC[/J_ARRN+9MN,A
M0T;?7E?UK?/_`/<3QO"F4%Q4HRW<;'UW_P`&YO@2RL_V;?%OCI#B?4_%I@D)
M&?DAACVC_P`B/7Z2D'&`<5^8_P#P;C?$JUO/@KXW^%TETAN-.\11WL4.>?+G
MA"Y_.%C^%?IQD=,UU94_]@@?/<;PJ4^*\5">ZD%%%%>@?*A6%\1]*M=<\':E
MH]ZH:*ZL)H9`1D%60J>._!-;M<S\7O%&F^"_AYK/BO5[A(K73=(NKNX>1L!8
MXXB[$^P`J*G\-FM!2=>'+O=?F?S!^--&M/#GC+5_#UB28;'5;FWC+=2$E90?
MTK^D']BC7KOQ?^R9\.O$=Y<%WN?!VG.[GJQ^S1J23[E2WX^U?S>>+=9C\1^*
M]3\0HH47^H37(4'IYCL_'YU_2=^R9X3N_`/[,?@'P;?0>5/IWA'3X)XQGB18
M%##\Z^:R&*6+J-'[9XM17]CX!3^)I?\`I*O^A^.O_!>[7KW4OV^+O1IY-T.F
M>&;&*W![!O,<_JU?87_!N7X5T^Q_9@\6>++?B[U+Q<8)FV_P0PQ[1_Y$:OD_
M_@X%\'W6B_MQP>+&C80:]X1LIH21P?++QM^H'YU])_\`!M[\3;/4OA/XZ^$L
MMTGVC2]:BU&*(?>V31A2?SB`J,-_R/))FF>P=7PIP]6EM[M_Z]3].Z***^K/
MPH*8TI`!"]:?6;XCOY=-T&YOH)-KPPED8C(!QZ>E*^HXQ<I**W;L:._CGTIO
MFC&<5^&]Y_P7D_;[MO&KZ5_:?A3RDU1K<J/#9;:GFE.<2Y!Q@Y/KTK]L?!&M
M3^(O!^FZU>,#-=6,<LQ48&\J"<#L,YKFPN+IXIRY>A[N=\.9IP_&G+&0LJBN
MC1?[S'W7^=?B%_P<'C'[:FFG_J3K;_T;+7[>OU?ZK_.OQ"_X.$/^3U-,_P"Q
M.MO_`$;+7GYW=X'3^MCZ7PO:7%M/TZ'`?L3?\%:OB]^P]\)9OA)X#^&OA[5K
M2;69M1:ZU2:X$@>1(T*XC<#`$?Z^W/L7_$1O^TW_`-$4\&_]_P"\_P#CM=A_
MP1R_X)U?LC_M7?LM7GQ$^-_PT.K:S#XLNK-;H:K=0_N4B@95VQ2*O!=CG&>>
MM?7'_#D7_@G-_P!$+;_P?W__`,>KEP^'S=T(^SJ)+S1]=GN=>']#.*\,5@Y2
MJ*3N[O\`S/A4_P#!QI^TRQWM\$O!IV*2/W]YP?\`O[7ZG_L;_&[7/VAOV9?!
MWQL\2:7;65[XBT6*]NK2T9C'"SY.%+$DCZUXQ+_P1&_X)S@9'P/9?7_B?W_(
M]/\`75](_"KX7>#O@KX"TKX6_#S118:!H=DMMIUGYSR>5$O1=SDLV/4DFO4P
M5',(/_:)J2\C\^XHS3A;&481RO#NF[Z[_JV=9UKX^_X+G_\`*.SQ</\`IXLO
M_2F.OL$8QQ7Q]_P7/_Y1V^+O^OBR_P#2F.NG%?[M/T9Y?#/_`"4&%_QQ_,_,
M/_@A\<?\%)O!I_Z<=3_](I:_=SXA>$/#WCKPAJ7@_P`3Z5%>6&IV3VMW;2Q[
MEE1QM*D'C!!Q7X1_\$/S_P`;)?!O'_+CJ?\`Z12U^^KQQ[?GR?>O*X?2E@&G
MW9]EXK2G#BE2@[-1C^;/YR?^"@G[(OB3]BG]HJ]\!"*Y.@W<C7_A34V./.MM
MQ'WO^>L>5!P<@D-WQ7ZN_P#!''_@H(W[4_P+C^'?C>]CD\;^$+9(-2)?#7MO
MNVQW2J>3P55CS\V#GY@*[[_@J?\`L0Z3^V;^SG>:+H]G"/%6@1S:AX5N)(P2
M;E5!\@GJ$EVA#[[3VK\0/V9?VB/B3^Q%^T99?$W1(+JWOM%O7L];TE_D:>`-
MB:W;CDDJ`!TW(#U`KAGSY/B[Q^"70^DH>R\1.%72;_VJ@M/-?\,?TM2MFW+>
MU?S8_P#!0H#_`(;A^+H'3_A/M7Q_W^>OZ&_@I\9O"'QZ^&>E?$_P)J\=YI>K
M6B3VLJ,#\K#H<=&!R"/:OYY/^"A*[?VX_B\GIX^U@#_O\]=6>ZX>G+S7YGE^
M$U*I0SO%TZFDHTV?IQ^S&^/V;/AZ,?\`,CZ3_P"D<5%-_9D_Y-M^'O\`V(^D
M_P#I'%17<HJQY%5+VLO5GX_>"_\`D<=(_P"PK;_^C5K^HGP)_P`BII_'_+G%
M_P"@"OY=_!`#>,](4G'_`!-+?_T8M?U$>`]P\*V".,,+*+(_X`*\SAQKV<T?
M2>,;7M\(KZJ+-BOA_P#X++_L#7/[5/P0E^(W@/2U;QGX0M6FTX``&]MLAI;8
MXYY&YE_VA[U]P54O;6+[*[7$F4"?/NZ8KW\10AB:+ISV9^1Y9F>*RC'T\5AW
M:47^'4_G-_X)Y?M@^(OV)/VC]-^(-PUU_8EW*EAXPTT-S-;,Q5F"GK+$VYN>
M?W;`<G%?1/\`P<#>*_#/CCXQ_#GQIX2U6*]T[4O!1NK.Y@Y22)I&*M^(_6LS
M_@MG^P._[.'QA'Q\^'^F`^%/&MU+)=)''B+3M3#>8X(_A23<SKZE67C.:^._
M'/Q7\4^//!GA3P/K\I>#P=:7%II+L^YEMY9_/6(^H1BX'L0.W/Q>)K5L)2J8
M.2]/,_I+*</@^(,VPG$."TDERU%W6S;^9^M__!M]S^RMXR'_`%4.;_TALZ_1
M<G#X'<5^=/\`P;?+G]E3QF<]/B'/_P"D%G7Z+JIDRP.*^HRI..#C<_!^.+3X
MJQ37\Y^7W_!QG^SS?:YX6\)_M)Z!9/(=$D;2=;*1[MEO,1)%(>^!)'L^LJ5\
M<?\`!(3]KS3?V3OVM;"X\87GV7P[XJC.F:S(6.V-W.Z"7GIME)5C_=D)[5^[
MOQA^"_@[XW^`M9^''CZR2[TK6[![2\MW0?<88W`]F4_,#V(![5_.[^V[^Q7\
M1_V)?C%=_#KQE8RW&ESS/-X=UEHCY&HVW(['@CD.F<\\''(\O-J53"8J.,I*
M]MS]'\/,?A.(,CJ<.8N:BW?E;ZW_`,M#^D/0K^SU*V%W83+)"Z*T;IC#*<D$
M8]1S^-7J_''_`();?\%KX_@KX=L?V?\`]J-Y[K0K6-(-"\5KOEDLHE)`CN1\
MS,B@J!(/NA<$=#7ZN_#KXZ_#'XL>&[?Q9\.O&VDZS87*[H[K3KY94(R1U7Z=
M#R*]G"8ZCBZ2DI*Y^89_PSF?#V-G0K0;BG92MHUT9V-07LD*C9*"=RG:`.OM
M56]\1V>FVWVS4)8HH@I:1WD`"@=R:^._V[_^"RG[._[,FB7/ASX?:U8^,/&C
M1R1VVDV%T&@M9,?*UQ,,H@!'*@ECC&!G-;U<11HQYIR2L>;@,KQ^:5U1PU-R
MD^R.`_X+S_M@:+\)O@$/V?/"FKHOBCQF5AO(T8%K32URTC^Q=PB#ZD_PU^97
M_!/+]GK4OVFOVP/!?PRM[-Y+,:HE_K+A,K':6^)I-W8!L*GUD'K7"?%KXL_%
MC]ISXM7GQ$\?7MWK?B;Q%>(#%%$S._\`#$D4?)`12451R!@X;J?V@_X(Z_\`
M!.S4OV/_`(;S>/OBC91)XW\2QYO+<*"-,ML*4M5()&X-N9R..5'\()^7C[7.
M,SYK>Y$_<\4\'X<\&RPBDI8FK&[?6[W7R/M70K(V$36Z*!$BJL:J>@`Q^%7R
M,C%16\?EDC=V'%2U]=9+1'\^)R:O+=Z_>4M2M(=1L)+&XA62.9-LD<B@@@]0
M0>V*_%C_`(+/?\$6[[X57&I?M:?LJ^'"^@SO+=^+_#%JNY],8G<]W;+SF(Y8
MM&,[>"HP3C]L3$>S8_"JNIZ9;ZE$;2]1)(G0JZ.F0P/4$'MCC\:Z,+BJF$G=
M;'BYSDF$SG#\E5>\MF?R(2)%<J&0`#`/#<8_PK[`_P""'_QNT;X'?MZV'B77
MKQ8["]\&ZW'<R,,!1#9RWI'/3(M%_/'6O:O^"YO_``25L?V>?$%S^UA^SKHF
MSP?J=V#XJT6TC"C1+B0?\?$>,%8)&!##D(\@Z*>/SC\(:A>:=K=G=6EQ)`Q9
MX6DC?:2DB%&!/8%6(/L37T&(Q'M<MG..ME=GY+DN2U,MXSPN$KNT95(QOY-G
MTE96_C3]N_\`;.5Y3++JGQ'\<;CA>(89YMQ8CLD<9P?]F,BOZ-/A1X)T/X:_
M#G1O`&@6?V:QT;38K2TA'\,<:[%_,`'\:_(C_@WA_9I;QU\;?$O[1FK6F;/P
MA9QV6EN\>0UY<AG?'^Y&.1V\X<\5^R=O:J8E\N8D;<`XZBOSS(Z-J,JLOM-_
MF?V#XFYFJF94\MI.\*$$OG9?H3SH9K9HU&2PQ_\`7K\R?^#BW]G#4O$OPW\(
M_M(:!IK22>&9)=.UUD3</LLS*T3MZ!)L\]O-R>`:_3I5V@#/2N6^,GPN\+?&
M+X<ZO\-?&NFK>:7K.G36E[`ZY#1NN#^/<'L17I8RA'$X>5-]3XOAW-)Y)F]'
M&+[+U^>C_,_!#_@E!^UQ:_L@?M:Z=KOBO5?L_AKQ+!_8WB#<^$CC=PT<[9Z;
M)$3GLK2Y^\*_H,M-3L]0B2YLYDEC<`JZ'((_K7\X/[='[%WQ'_8<^,EU\/\`
MQ7833:%<R[_#>MF/]UJ$)`PI8YQ(HX9.ORDC.:^L/^"7/_!9]?@;IEA\"?VH
MY)[KP[:*(=+\4;C)/I\0&U8YDY:2,'`5UR5!Y!QFOG\MQLL)-X>KI;8_6^.^
M'(<2TEG>5>_=+F2W?_#'[,QGDBG5QOPV^.OPN^+N@P>*?AEXRT_6M/N(U9+J
MQNA(N",C.W.T^S8/'2NBN?$-G:PFXDFBVCJ1)G'UQTKZ=3@U=-?>?B%2C6I3
MY)P:?:S+4LJPC)%?`W_!=G]M;1/@_P#L\CX`>$];4^)/'D3V]PEL06M=.!7S
MG?\`NK)D1XZL"^,[3CK_`-NS_@L5^SK^R[X>O?#'A+6;+Q?XR:(I#HFCWH>.
M!B<!IYAE(QU.,[N.G-?B=\7?BS\5?VH/B]>?$3QM>W6LZ]K]\%@A@0M]XD1P
MPH.0H)VA1G)Y[UXF:9BJ,73IN[9^G\`\%8C'8N&8X^/)0AKKI>WJ=1^PC^SK
M>_M0?M5>%?A186,DUK/J"76L*R[MEA`ZO-G_`&2G[LGU<#N*_I2AM62%(F`^
M50/7I7PU_P`$:?\`@G7=?LI?"QOBO\2;/R?'7BF!?MUNZ9;3K,-N2U![%B%=
MQW;`(^0&ONL#!SFNC*<-[##\SWEN>7XB<1QS_.N6D[TZ7NQ_4_.S_@X0_9<U
M'XF?L^Z-\??#&E-+>^`);C^TC'G<=.G5!(YQU\MXXW!/0;O4U^;7_!-G]L:X
M_8Q_:AT[XC3S7']AZI&=-\36R*6S9O(A+JO]Y&4.,<X5@/OU_1!XW\':5XZ\
M.77A/7K:*XL+^UEM[VWFB#I-$ZE71@>"""017X%?\%.O^"</C7]B#XHW&JZ)
M87%]\/\`5+G.@:P1G[,S#=]DF;)VLOS89L!E7/7(''FN'JT:RQ-%7?4^EX`S
MG!9EE57A_'OW9?#?[S]]_"_C#PYXTT>U\0>&-7@OK.\@2:UN;:0.DD;#*L".
M"".<UJ1D;BO<=:_!7_@F]_P5P^(?[%\\'P\^(&FR>)?`A<F.S\XBYTHD'FW+
M':8^F8SCN0PY!_7W]GO_`(*&?LG?M+Z+!J_PO^+^DS7$RJ9M+O+@6UW"Q'W&
MBEVL3U&5!4XX)KT,%F%'%T[WU/B>(N#<VX?Q#4H.5-[26J_#8]PK)\5#=X>O
MO^O-_P"568->L+N`3VLRNI&>#C^E<[\1O'?AKPUX4O;W6]8M+6+[*P\VXNXT
M7D8SDL*[95*:IR=^A\Q0I598F$5%WNNA_,IJ"E?B)/[ZZ?\`T<*_IZ^&O_(@
MZ*/^H3!_Z`*_F%NW2?X@S.C9']L@E@01DR+D#Z'C/>OZ>/AHV?`.B$=]*@_]
M`%>!D/O5:K7<_7_%Z,HX?+[_`,G^1LOT;_>'\Z_$+_@X0_Y/4TS_`+$ZV_\`
M1LM?M[)PC-[K_.OQ"_X.$/\`D]33/^Q-MO\`T;+77G&F#1\WX7R4>+(-_P`K
M_(^R/^#>'_DQ_4".WCV^_P#2>WK[^K\\/^#?7Q9H&B?L4ZA9:KK%I;2MXYO7
M1+FX5"R^1;\C/;@_B#7WD/B5X([^*M-_\&$7_P`575@:E-82*;1X'%=*L^),
M4^5_$^C[F[16"WQ*\$=$\4:<3Z?VA%_\52)\1_"UQ<BTL]?TZ61L;8TOXRS'
M(X`!))YX%=:J4V[)K[SY_P!E5_E?W,WZ^/O^"Y_/_!.WQ=_U\67_`*4QU]@]
M:^0/^"YR_P#&NKQ?)_=N++C_`+>8ZRQ37U:?HSV.&G;B#"O^_'\S\PO^"'YS
M_P`%(_!G_7CJG_I%+7[]CD#-?@'_`,$/,O\`\%(O!N!TLM4'_DC,?Z5^_HZ5
MY>0*V!MYL^R\5VGQ/I_(OU*VH1228"*"`K9XZ>GZU^//_!>C]@J7P-XK'[8O
MPQT9ETO6)H[;Q;:P)\L-T5_=W(4<*'V[6/3<<GK7[&2QM)]U\<$5S7Q0^$GA
M'XP>`M4^&_CS3H[[2=8LWMM0MIDR)$92I^A`.0>Q`-=^/P<,;A94WN?(\,Y_
MB>'<WABZ>L5I*/='X_\`_!"W]O>U^#GQ%;]EKXE:OC0?$MRS^'KB5LQV=^5)
M:+)Y42X``/&Y5[L:^4/^"@LB3?MO?%N5&&'\>:N0N><>?)@X]#1^V+^S/X]_
M8G_:1U'X7ZM-<1OIUV+WP[JN=IN;3S0T,Z'^\&7!]&5A_#7GWQ3\?:G\4_'^
MM?$?6X$CO=;O)[R\6,Y!E<$L>>>3S^-?&5<555*&#J+6#1_2&3Y/A:F:U,[P
M37LZ]-W2[GZ\?LR?\FV_#W_L1])_](XJ*/V9"/\`AFWX>\_\R/I/_I'%17UT
M?A1^,U4_:R]6?G/X-_X)V_MNVOC'2KF[_9A\9QQ1:E`\KR:0RJJB126)]`.:
M_H?\"V]S:>'+2UO3^^BM8DE&,;6"@$?45KB-!SM%.'TJL#EU'`7Y-V>#Q1Q=
MF'%4Z<\5&*<>R"D=$=#&Z@J1@@TM%>@?*'FW[4W[/?@;]I;X,ZW\(/'6G^=9
M:OITT(<<O;RE?DE3/1E;!'OQT)%?S[_&#]@O]JOX1_$S6_AQ=?`SQ9JITB^:
M!-4TCP[=3VUVG598Y$C*L&4@\'@DCJ*_I1J.2VBD.6B0_45YV.RVEC6FW9H^
MTX2XVS'A1U(TES0GO%NWZ,_/_P#X-\/A[\0OAQ^S+XLTCXA>"-9T.ZG\>S2I
M:ZSIDMK(\9L;4!PLB@[21C\*_0&'[O2A((H^(T`'H!3ZZ\/15"DH)['SN<9C
M+-LRJ8MQY>=WMO8*\S_:4_9>^#?[4?P[N/AS\7_"<&I6DP!@D(*S6\@P5DCD
M7YD88ZCJ,@Y!(KTRBM)14U:6J.&C7K8:JJM*3C);-'XB_M5?\$"?V@_A;J=U
MK_[.=['XVT4R/+%9F407]NN?]7M8A)C@D;@RGCE>17RCJ?PS_:Y_9UU42S^!
M?B!X.NH),I<+97MJQVC&%E10#TZY/U-?TSE0W!%1M:PL<F%3_P`!%>-6R+#5
M'>FW'T/TO`>*.;T:"HXVE&O%=U9_?9G\S>H?$[]L3XM.?#VO>.?B1XD:7$;6
MT^IWMT7]%VL6+<]N:]-^`G_!)/\`;G^/E_`(OA!J'AFPEE'F:IXOMVM(XP3]
M\1MB60]P`B_6OZ%Q:VHY^S(/?:*>B1K]Q0/H*RAD-.3_`'TW+\#JJ^*^,I4>
M3`86%%]UJ_R1\:?L`?\`!'OX'_L<S1>/?%$B>+/&;H2VL7EOMCM&)Y\B+)"'
MI\YR_7D9Q7V(EO#$5PN-OW0O0?\`UO:K-&!Z5[5"A2PT.6FK'YGF.8XW-L4\
M1BIN4GW&1$%V.#FGT45L<*OU"FR@8IU%#U&8'C?P%X/^(_AC4/!GC?P];:GI
M>JVCVVH6-W'NCGB9<,K#W'\AZ"OYFOVY?V/_`!)^QC^UAKGP.DTZ]GTVWNQ>
M>';R2$L;G3Y6_=/N'#$$,C8_BC<=J_J$K%U/P+X8UJZ2^U?P[8W<T8`66ZM(
MW90#D`%E)`!YZUO1Q$Z4)P>JDK'D9AE%''XJAB&[3I24D_1IV_`^?_\`@DU^
MS8/V:_V+_"_AG5;'R-8UBT36-:3;AH[BX42&-CU)0;4_X#7TP%7`VC&.E-@M
MX[<;8T"C:``HP`!^E25S0A&G%1BM$>_B\35QF)E7J.[D[A45P@DPA8C@]#4M
M%4CF:NK'F'[1G[,_PA_:?^'UQ\.?C%X4M]4L)GS&\HQ+;R8XDC<?-&XSU!%?
MDU^UC_P0.^/_`,-+NY\0_LZ:I!XVT/K;Z;,1;W]NN?NX/[N<#KD,I_V:_;2D
M*J1@@8KBQ&7X3$ZSCKW/I.'^*\[X;FOJE3W>SU1_,QJGPI_;!_9TU/S+KP%X
M_P#!TT1^:[BL[RT!9>X:,!6QG@ACU]Z74?BC^V-\5T7PYJOQ!^)'B,,/EL[C
M4;Z\WCV3<W'UK^F-K:V/WX%/U44GV6S_`.?9/^^17F/(FG[M5I?UYGW7_$5%
M/WJN`IREU??\#^>#X$?\$H/VY/CYJ$$>F_!O4/#-C+(%?4?%MLUC'$IZML;;
M(YQQQ&"217ZF?\$__P#@CE\$OV2;F/Q]XVF3QAXU3:T.LWUIMCL&P0?LT9)V
M'G`<_/@<;<MG[75$7[J`?04M=F'RC"4-6KONSYK/?$#/\\INDY*%/^6)!;VU
MO;1".`;5'``Z?E4_2BBO3C%15D?#W;>HV3&0:YOXD_"GX=?%SPK=^"OB/X3L
MM8TR^C*7=E?0B1)![@]QP01R"`1S7344G%2T94)SI34H.S74_(O]KO\`X-[_
M`!#9WESXR_9#\8136S?O/^$7UN8J\1SR(K@@[AC^%P#Q]ZOA;XD_L6_MA?!&
M_E?QY\`O&&GFW8@:A#H\TUNI_O":$.I'_`OP%?TNX'3%->*)_OQ!OJ*\G$9)
MA*KYH>Z^Z/TC*/%'/\OHJCB%&M#M)'\QFD_%K]J3PY:C3='^(_CZQC0;?)AU
M>]C"^N!N&.:U;#X._MD?&B8QVOPQ^)/B8L=I^T:9?W<:G_>9"J_F/J*_I;-I
M:DY-JG_?(I5MX0<^2@^@K".223LZK:_KS/0GXI1M>E@*<9=]_P!#\&O@%_P1
M'_;M^*6L6-]XO\*67@[3@Z.USKMVIE`W9P((BYS]6'45^Z/@O2I-#\*:?HT\
M@D>SM5@=U7`8H-N0,G@XK7"*.BTM>GA,%1P<7[/=GQ'$G$^9\45XU,6U[NR6
MR*TI/EG`].OU%?D/_P`%O?V2OVD?C=^UE8>*_A+\%_$/B'38?"T%N]]I5B98
MQ(LDA*G'0C(K]@::T:-U4?E58K"PQ=+DEL<_#N>8CAS,UC:"3DE97V/YP++]
M@']O[3H?*T_]G+Q[!&7W;(=.D52V",X!QG!Q4G_#`_\`P42_Z-Z^(G_@'/\`
MXU_1T(8\8VC\J=L3^Z/RKSO[$I6MS,^YGXK9K4FYRP]-M^1_.&/V"/\`@HCG
M`_9Z^(F3_P!.<_\`C7H'[*_[%/[>/AC]H_P+X@\4?`OQY!I]EXNL)M0FN[:5
M(X84F4L[DGE0"3@^M?OYM7^Z/RH"J.0HS]*=/):,)\W,SEQ?B7F&,P\Z4L/3
M7,K:)B1;O+7=UQS7R]_P6&^%WQ`^,7[#/B;P)\,_#%]K.K74UJ;?3M.BWS2[
M9T)(!],5]1TA4-PPS7K5*<:E-P>S/@<!C*F7XVGB8*[@T]?(_$__`()"?L7_
M`+5?PH_;L\+>/_B5\"?$/A_1[.WU`W.I:E8&*./?93(J%B2"2S?I7[8CD9I!
M'&#D(/RI:PP>#I8*ER0/2XBX@Q7$F/\`K5>*3LEIY!1THHKK/!/C?_@KW^P?
MI_[7?[/5SXG\'Z,)/''A6)KWP^PCR]TN1YEJ<`L0R[MH'\6/4U^*<G[)_P"U
M(C%&_9F\?'$;Y)\(WI.-I&,"'&2<<YQS7].;*K#:PX-,-K!G/DK^0KR<;E-'
M%U543LS[SAGC[,N',#+"QCSQ>UW:WX,_//\`9Q\#>.=,_9Y\!Z;JO@S4[6ZM
M_!FEQ7-M-8S*\,BVD09&!3@@@@CVHK]#?(C_`.>:T5V+#V6YXLN(:LI-\N_G
M_P``?11174?.A1110`4'/8T44`%%%%`!1110`4'/8T44`%&`.@HHH`****`"
MBBB@`HHHH`***3<OJ*`%HI-R_P!X?G2Y![T`%%(&4C(8$#KS070=6'YT`+10
M"",@T9'7(H`,9ZT8'H*,CUI-RGHP_.@!:*3<O]X?G1N7.,B@!:*3<IZ,/SH#
MH1D,/SH`4G!Q14<LP4A4(^8'!S]/\:YKPW\7OAQXT\4:UX(\(^.],U+6/#LB
M1:[IEE>(\]@[J&02H,LA*LK#(Y!!H%=7L=311D>M(64=6'YT#%HI`RGH11N4
M]"*`%Z=336=AP!S7#?%']H/X:?"KQYX/^%_BOQ&MKKOCNZN[?PO8^6S->RVT
M0FE4$`@;4(//K796SF2!2\VXG^+UJDNIE[:/.X+5HLT4A91U8?G1O3&=PQZY
MJ346BD#*>C#\Z-Z8SN'YT`+12!E/1A^=&Y<9W#'UH`6BDWH>CC\Z-Z9QN'YT
M`+12;E_O#\ZR?'7CCPK\.O!^I>._&?B*STK2-(M7NM3U.^N%C@M84&7DD=CA
M55<DD]!0)M(UZ*R/!7BK1O&WANR\8>'-=M=1TS5+.*[TN^LYA)%<VTB[XID8
M<,KHRL".""*UBZ#JP_.@=Q#(<<+0C,V<C%<[\2/B+X:^%?@/5OB1XVU5;'1]
M#L7O-4O&1F$$$8W.Y"@DX`)Z4[X6_$+PS\5/`>D?$OP9K27^B^(=*M=2T>]4
M8%Q;3PK+%(`><,CJ>?6G;0RC6C*5D=%11UZ44C4****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****``G`S7FW[5OQ9U?X$_LZ>-OC-H6E6
M]]>>&O#EUJ5M9W3E8IVAC+A&*@D`XQD#//%>DDX&:\7_`&^O#^K>,?V+?B;X
M;T31YKZ[OO!.HPVMG;1EY)I&@8*B@<DD\"KI_$<V,E4CAI<FY\P^$/\`@I[^
MUSID'PD^+/Q>_9I\.Z7\-?BWKVGZ/I-W8^())=5M9;P@6\\L6S9Y4A(88.0"
M-V#77?%?]OO]J'Q'\3?B1X:_9(^!_AC7]!^$05/%FI^)==GM)M1NQ`)Y;6QC
MAB<.Z+E29"HW+@9R,^?_`!I^$OQ,U7]@3]COP58_#_5I]2T#Q/\`#>3Q#906
M3F>PCMHK47#2#^'84;=GICWKS7Q7^SY\*O@1^V+\7YOVNOV<?B+XDT+QWXE?
M7?!?B/P1;ZA<P7,=RBF>QEBLG!617WC,@P0N00#7=%4'&[6I\Q4JYG":I\[M
MIJ?2_P`!O^"E;?&SX^^%?`UOX8M[#PIXZ^%!\9>'-7N7Q<&2.=X[JQ<#Y&,>
MS>6X)!SDCFN9_9I_X*RW?QL^%/QP^)_C+X;6NA#X6Z5-K7AZW^U28UG3"MY]
MFF(8*0TCV94@9'S+SS7FW[>/P.\5?"S]G7X)_'C]CK]G_7[6_P#"$%_IEEX-
M%FSWUGI^KZ?-`Z2H22IC+ACR=K`'M7(_M??L8?&7P!=_!WX(_![P%J.I:-\2
M?AIHOPZ^(>J65H673HK&^L9&OK@C&&9))\D]2CU2AAIZ)&=;&9I1::;?+OYW
MT_4_2+]E[XG>,/BO^SAX/^*_Q!\-6^BZQXBT"'4KW2;:1G2T,J^8L>6Y)"LH
M/;.<<8KXQUO_`(*I?M::G\"?%W[;/PQ_9J\-:A\'M"N+RWTR6[\1W$>LWPAE
M,"WX@2(QBV\TC<N\2!%=@IP,_>FG^%].LO!<'A2RC:"UM[!;6**,XV1JH50#
M[`"OR8UCXH?%+]FK_@E5\2/^">OC[]G;QB?&/A_0=7L?[:BT9O[%N-&:220Z
MC]K!V(/(\TA"=Y=57&6%<]",.=QM<]#,\3BZ$(N+LN1M^NECZQUK_@H%\?OB
M!KGP]^$/[,/PH\/ZEX\\7?#2T\:>(3XIU6>WTK0[6>.,JC/`DDDCO(S(H"X`
M`)/S'''>//\`@K)\3O#?[..E?%*R^`T5QXXM_C%%\/O&/@Q-2^2VO"MR2;6?
MCS-S11;=X"CS""/ES7AOB#X`:+X;\=?!G]ICXT?!;Q?XJ^&WB3X!Z#HU_?>#
MOM4EUH=_!;V\D3S0VDBRF-T.,@,!@]#7:?&3X"_#K6/V7?ASJ7[)_P"S1XQT
M'2K_`/:8\.:IJ5AK>FW*7URD,DBRW\D<[,\</)^9N2`#WKHY</\`RGGTL3FD
MZ#DY/9?BD>[_``B_;Q_:!\*_M(W_`.S-^VG\(/#?AW4#X%F\7Z+JOA+6IKZT
M^PPR%)HI6E1&\Y-K$X&"!P37$Z;_`,%3_P!H>/P'H_[7WB/]G[0;?X&:YXC3
M3K6ZCUV=_$$%G)<-`FH2V_E^3Y)9<E1(7`(XXKH?VH/@CXX^)_\`P4L\+R:=
MX=OQHM]\!/$&D7.MQV[-;6]S/-B-'<<*Q5V('<"OF+]E[]GK]F[P/\/-#_9E
M_:G_`&*?BE??$#2-8.FWB65GJ,VEZB/M6([])5E-NL)3:YR01M)P,XJ.3#\M
M^4*N(S2%54U)\J/JC3_V_?VF_B+^WEXR_9#^"_P"T*_TSP1?Z8^L^++_`%AH
MHH=/N+>":0A=OSW&Z8A(QD%5R3UIW[2W[87[=_[-.F^(_CSXJ_9T\$2?"OPO
MJ8BNXH?%<QUV:P,R1"]2(0^0,EP?*,@;@\=*O_L9_#7Q?X7_`&^_VF?$NI>#
MKZRTS5=5\.G1M0N[)TAO%BTN)',3GB0*?EX/!X[5^?GCOX+:YXT_9+\>>$_C
M)^R!\1?&'[2UW?7LVH^(M4TJXGMM/@%R6\^UN`P@6`0*^R*/<Q9P,<TH1IR>
MBL5B,3CZ.'2DVY-MJWE:Q]6?M%_'#]MK5O\`@I)\(=&^#&E^%IM!UCPEJ&H^
M'-'U3Q-=V]OJ-N4MVFN+Q(X2$EB#GRE4LK<[MN!GJ_"W[9WPR^!/BK]I_P"*
MWC#X+Z)H=Q\.-3L$U[4O#Z[;SQ'</9(T8E<]6W/Y:GC@@G'-87Q^U#QO\"?V
MI_V:/VC==^%?BC6?#.B?#V_T37;C0-)>]EL;NXBM1'YL48WKN.<G&/E/3!KA
M?BO^R-\9?VEO#/[9?A+P_P"!]5M+OQ;XIT?4_"'VZW-NFI&VL[>7RXV?`))C
M*'/`8@$YSB^6F]'L<].MF$-8MN5V]?-(]AT#]OS]L#X:^+/AW<_MA_L_^%O#
MOA#XI:I!I^C:EX:\0375WHEU/&9+>"_CEB107PJEHRVW=ZC%8&L?\%%/VZ_%
MOB_XRZ+\#_V9?"&I:9\&O$E[;ZKJ&N^)9H3J-I"C2Q)`JQMFX*([,"0JYC&<
ML0.8^,WQ8^(?_!1[5_@W\"?#'[-_CGPS=>'O&]AX@^(6I>)/#TEE:Z.;*-_,
MA623_6NSEU7`P0%]:](_9)^''C_0]6_;!D\0^!-4LEU_X@:C<:+Y]FRKJ,#:
M<$26`GAPQ&,CO4N-!0YFM3H]MF$L0J<)/EL^C['TS^R3\>=/_:@_9P\'_'S2
M--DLX?%&B1WOV.4@M;NV0\9(X.U@RY]N:^5[']OO]N?XJ_$3XL>`/V?_`-G/
MP??K\(/$<]GJ5_KVOSVJZC$D:R)'`J(S?:'7S#\V$&U<D;A7L7_!)+PGXM\"
M?\$[OA=X4\<^&[O2=6LO#S+?Z=?PF.:"3[1*=KJ>AP17R/\`L^_M<:Q^R_\`
MM%?M26^H?!#QGXGMM2^)4SZ)/X5T-[U9-26V5!:3;,F$LAMR&?"D`\]JQIQC
M-O0Z\;B<33I8=.5F[I_)7_0C_:F_:^UO]HCQM^QC^TO\%OAT^HZUJVN>)$L?
M#%Y>B%4U!K.*V>&63;\L:2,Q9QSM7(SFOIC]EC]L?X]_$?XL_$O]FO\`:$^#
M^C:5X\^'VE6FIP?\(OK$EQI^JV]S&S0;'E17C<L-IR,8)]#7S1\#?V4_C5\)
M=3_8KLO$/@'4GO+#Q5XLUOQ8D%NTB:+]NM%,,<[KD1\,%(_O`@?=KN/CI\./
MVF(?VM/VI_&WP-\*ZI:ZSJ7P=T*V\'ZK%$8X[J[C23='#*QP74%OH371RTI1
M47H>;AZF84Y2KR;=[-KOHCNH?VV?VTOA!\5O`NA?M<_`WP3I7AGXB^(H]#TZ
M3PCXGN+V^TJ]E1C"EPLT4<<BEL`M&Q"@D\D8J+X;?M[_`+4'QI_:H^(7P/\`
MAO\`L_:'+X;^&/BUK+Q1XIO]99-MF8FV>7%M!>Y9HY<JO[M5VG.6%?'V@_!S
MX<Z[XE^`.N?`/]C;XAVGBG0_B'HDWQ+\<^)M!NUE649,T,DLQ)FS(9&+H"BX
M&6[5]H_L$_#_`,9^'/BK^U1?Z_X5O[*+6_BO-=Z//=V;QB\A^QJN^+<!YB[@
M>1D<\43A14;HJAB\TK34+M+5_@>-M_P5[_:\T;]FNT_;;\3?LR>&D^&EIK\N
MD:Z++Q+(VHRRB_:T$UM$Z!#&"%7#DL9-W`0`U[?\$OVU/VI8?VLM'_9C_:S^
M"'AOPZWC+PU=:YX2O/#NO27GDI;X\VVN]Z*!*H.=R%E.>O6OF3Q#\$OC5)_P
M0M@^&D'PKU]_$8^)4ER=#DT]UNC&/%$DN_RR,[/+^<>JX/>OI#]H_P``?%+4
M?^"H7PG\;^"_"UW+:V'PO\3PMJWD'[);7DB)Y"2/T5F(/<<"L^6FUL5"690J
M<RE)VL_\RM\>OVT_VX?V9K6_^.7Q2_9U\#I\+=-\0I8W4-AXNN)-<%C)=BWB
MO!#Y(@((9&\OS-PY&*VOC1^W9\;?$/[0,?[)?[%?PAT;Q+XKL_#D&O\`B?5?
M%>JR66EZ59SL!#&[1(\C3N"K!`I`4Y-?GI\0/@O_`,)I^R?K?A_Q?^Q]\3O$
M?[1;:_\`:/$OBW6-'NIA8!=15EFMYW9HI(O*\M5CC#'[Y[5]9)>>/?\`@G_^
MW1XJ_:5\7?!7Q9XE\`?%;P1H5K<ZKX4TA[^?1=4TZUCMQ!+;1YD"R(I.X#`;
M@T_94K:J[*CF&-E5:;:AUT9Z?\1?VR_VI=)\>>#/V4?`7P<\&W'QFU?PK+KW
MBR'4?$-PFB:'9).\*2>=%$TTOF/'M0>6#ZXKF)/^"IWCA?@=%XKU;X1V%GXS
MT'XT6?P[\<Z%/J+O;6MS)<I%+-;RJNZ1=C;TW`9#<UY/^UKX-T3XC?M=^"OV
MY/BI^S?\1=0^&GB/X<?V+J=CIVGW<>JZ#>PWD\MO+<6MLZS;)4E(P`<9.<8Y
ML_'3X#^"6_83E^)'[&/[*WC73(=-^+>D>)]7\/:S9W":KK26<J;[E(;AFD9F
M7;C=AB%SCBFHPY5H$\5F-6O/EDTHZ)6W1]0_'#]JCXJ^`/VP/"?[*W@#P3HF
MI77BWP'J^MV-]JM])"L=Y:AO)B<(C8B=L*[CYE!!56YKY+_9,^-G[5&I_LZ_
MM0>*_P!H/P)X0\6^#=$\6^*CK=AJVOW-TWVZ*SM"=*CB:%5.GB/;A\A\R-\O
M6N]\%?%KQS^UA_P59^&'QU\-_L^^-]!\$Z+\/M9TZ+7O$^@R62W%PZ[W4H_S
M1@$JJEAASG'3GCOAA<>-O!?P0_;`_9(UWX,^,$\3>)O%'B_Q-H<Z>'9GL;RR
MGL;.*$17`'ER2NR,1$#NQ@TDE&/F35K8K%8KVG,U'7H]=$>O']O#QCX2^$WP
M`^#G[,OP#T?4_B%\4OASINKZ)X8>^-GH_AS3?L,#DRS*&811[]B!$8L(\<<9
M],U3X@_\%#=/^"MI))\#_AZ_Q*N/$OV2\@/BV=-&MM-$#-]O,WE><V'V1^4$
M#$L3C'-?+]MX"^,O[*VM_LN_MEO\(_$'B31?#_[/VE^$?'VCZ#IYEU#1]MI`
MPN/L_P!]U#/*KHHW`QCVJ[^W!\:=4_:GC^%7Q*UGX)?%1?@A;^*;Z'QWHUKH
M=S::A/(ENAM+F:WC(G:V+NPP.I!SVPO9Q;1M#&XF$)NIS<VR7D=?\1_VN/B?
M\6_V<?VD_P!F[]H;P+I'AWQ_X`\!7$VHGPWJ4MWIUY:W-DSQ3P22HDF,-R'4
M$$CBL_X6_MB_&SP%\$?V8_V1?V:OA_X8U3QEXB^`6B:W)?>-=:FLM.M+2+3;
M=`H:WBDD>1FC?Y0O``)X.:\:^$/P,U73=4_:OO?@K^REXA\"^%_%/PFAC\%Z
M'?:4T)NI1;R(2J'+*\A4-Y3-N7<<@<"N]^+F@_`1OV-_@5\,/VF_V7?B?>^)
M=$^#>A'PUXL\#^'KEK_2-22RAC-JL]N=]K.LL:MA_DYYS@UHHTO::ZHY(5<?
M*G*I=IVM_P"37_(^P_#_`,0?VMY-!L7\3?#7P=#J36<1U"&V\3RF..?8/,5"
M8P2H;(!(!Q17YL^#O"7_``<+IX1TI=$U"Y2R&FP"T36FMS>+%Y:[!.>\N,;S
M_>S14<L/([EBZ]OAD?L[1117`?6!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!UJ(V\3Q>6PRO3%%%-;">KL)]AM!\OD@9.>">M*UI:]XA
M[9S111=DN,>Q$NGV:*$6+`'0`GU)_J:!I]L/F6(##$_B22?U)HHIINXDHW>@
MZ*&*)2B,>1T-?&OQ._X)N_M5?&G1;_X6?%W_`(*+:MJOP[U6_+ZGX?M_`EO;
M:C=6ADWBS;4$N,[,[02(02N5/#&BBE&<J<W8PKT:>)BO:'UEX'\#>'_!/A33
MO!F@V*0:?I%A#96$"<"*&-%15&.@"JH_"MDVENRX>,'%%%)U)-W-H4:=-<D5
MH(MG&K;RO3/\1[T?8+,\B(`8P0!@8HHI<\F:.$)*[0"UMUX2+`[`'ITZ>G2D
M.FVC@CR5.3GG/!XZ>G04455W8AJ-]@%A;])DSSD4W^R[=/\`CVB"#'&TD>_\
M^?K112&FD[V'FR4X)B3(Z''.?6E%HI.77H<\$CVHHHV&K-;$@ACC38!@5XC^
MR_\`LC']GCQU\4?&-QX]763\2O&S^('M5TK[.-/S`D7V<-YK>;C8#OPG^Z**
M*N#:V,YT*56I'F6U[?<>S6]I:I\B*=JD8&3@8_\`U4XZ?:[1OBW8/R[F)Q^=
M%%2[MIC48I-6&#2K/<&\A<C(!QV[CW'M3O[/@C&$C"\8&***$W<;C%IZ"?9(
M3(%=<@CD9IXLHP,.I(R>K$]\T44YR:*BEM;H-DTNRE7;Y([G()&,C%$-A"A)
M,8;.?O#/?..>WM114J3>HG&$79)"C3;$'>;=0?8>Y/\`4TOV"W4Y6-0I;)&.
M"?7ZT44<S;L%HQ=TMR.32-/D7`@52>ZY!QV&1Z9X].U.&F6`D,OE`L0.I/&,
MX(]#SU'/3T%%%.[1,8Q:6FPOV"W(PB`=.A-,;1[)^MJ@YZJ,>OI]2?KS1123
M=BI*-]@@TC3H)"\=L/F.<$Y`X`X!X`X'`^O4U))I]F>L"],9'!_.BBEJM;A&
9$+6L1MI6G,Q9K-"2<DD4445%V5RQ['__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
